1. 40P Can we predict which TIL products will react against NSCLC tumours based on the immune infiltrates?. (December 2022) Authors: Castenmiller, S.; Kanagasabesan, N.; de Groot, R.; Guislain, A.; van Loenen, M.; Monkhorst, K.; Hartemink, K.; Klomp, H.M.; Smit, E.; Haanen, J.B.A.G.; Wolkers, M. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?. Issue 7 (2017) Authors: Gool, M.H. van; Burgers, J.A.; , K. Sikorska; , E.E. Schaake; , T.S. Aukema; Klomp, H.M. Journal: Journal of cancer research & therapy Issue: Volume 5:Issue 7(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. (November 2021) Authors: Joosten, P.J.M.; de Langen, A.J.; van der Noort, V.; Monkhorst, K.; Klomp, H.M.; Veenhof, A.A.F.A.; Dickhoff, C.; Smit, E.F.; Hartemink, K.J. Journal: Lung cancer Issue: Volume 161(2021) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗